Skip to content
10-Q

Quarterly Report

ESSA Pharma Inc.

0001558370-25-000779

← back to feed
Filed
Feb 11, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Feb 10, 2025 44.39M sh
Operating Cash Flow Q1 2025 · Dec 31, 2024 −$6.47M
Operating Cash Flow Q1 2025 · Dec 31, 2023 −$6.79M
Short Term Investments Q1 2025 · Dec 31, 2024 $27.24M
Short Term Investments Q1 2025 · Sep 30, 2024 $23.05M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $93.31M
Cash And Equivalents Q1 2025 · Sep 30, 2024 $103.71M
Stockholders Equity Q1 2025 · Dec 31, 2024 $118.77M
Stockholders Equity Q1 2025 · Sep 30, 2024 $124.61M
Stockholders Equity Q1 2025 · Dec 31, 2023 $140.68M
Stockholders Equity Q1 2025 · Sep 30, 2023 $145.63M
Current Liabilities Q1 2025 · Dec 31, 2024 $3.69M
Current Liabilities Q1 2025 · Sep 30, 2024 $3.3M
Total Liabilities Q1 2025 · Dec 31, 2024 $3.87M
Total Liabilities Q1 2025 · Sep 30, 2024 $3.51M
Current Assets Q1 2025 · Dec 31, 2024 $122.11M
Current Assets Q1 2025 · Sep 30, 2024 $127.56M
Total Assets Q1 2025 · Dec 31, 2024 $122.63M
Total Assets Q1 2025 · Sep 30, 2024 $128.11M
Eps Basic Q1 2025 · Dec 31, 2024 −$0.19
Eps Basic Q1 2025 · Dec 31, 2023 −$0.14
Sga Expense Q1 2025 · Dec 31, 2024 $4.21M
Sga Expense Q1 2025 · Dec 31, 2023 $2.22M
Rd Expense Q1 2025 · Dec 31, 2024 $5.47M
Rd Expense Q1 2025 · Dec 31, 2023 $5.38M
Net Income Q1 2025 · Dec 31, 2024 −$8.53M
Net Income Q1 2025 · Dec 31, 2023 −$5.96M